Таргетная терапия в лечении метастатических, рецидивных и рефрактерных форм саркомы Юинга и остеогенной саркомы. Обзор литературы
https://doi.org/10.21682/2311-1267-2021-8-1-57-63
Аннотация
Остеогенная саркома (ОС) и саркома Юинга (СЮ) – наиболее часто встречающиеся костные саркомы у детей, подростков и молодых взрослых. Пациенты с метастатическим распространением, рецидивом или рефрактерной формой заболевания имеют неблагоприятный прогноз: 5-летняя общая выживаемость не превышает 20–30 %. В настоящее время проводятся исследования в целях поиска новых мишеней и путей воздействия на эти опухоли. Цель данного обзора – представить актуальные данные из мировой литературы о потенциально эффективных таргетных препаратах для пациентов с метастатическим распространением, рецидивом или рефрактерными формами ОС и СЮ.
Ключевые слова
Об авторах
Д. А. Моргачева
ФГБУ «Национальный медицинский исследовательский центр имени В.А. Алмазова» Минздрава России
Россия
Россия
врач-детский онколог отделения химиотерапии онкогематологических заболеваний и трансплантации костного мозга,
197341, Санкт-Петербург, ул. Аккуратова, 2
Д. Ю. Панова
ООО «Современная медицина»
Россия
Россия
врач-терапевт участковый,
197341, Санкт-Петербург, Коломяжский просп., 20
М. Б. Белогурова
ФГБУ «Национальный медицинский исследовательский центр имени В.А. Алмазова» Минздрава России;
ГБУЗ «Санкт-Петербургский клинический научно-практический центр специализированных
видов медицинской помощи (онкологический)»
Россия
Россия
д.м.н., профессор, ведущий научный сотрудник, 197341, Санкт-Петербург, ул. Аккуратова, 2;
заведующая детским онкологическим отделением, 197758, Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68А
Список литературы
1. Rivera-Valentin R.K., Zhu L., Hughes D.P. Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy. Paediatr Drugs 2015;17(4):257–71. doi: 10.1007/s40272-015-0134-4.
2. Grünewald T.G.P., Cidre-Aranaz F., Surdez, D. Tomazou E.M., de Alava E., Kovar H., Sorensen P.H., Delattre O., Dirksen U. Ewing sarcoma. Nat Rev Dis Primers 2018;4(1):5. doi: 10.1038/s41572-018-0003-x.
3. Ferguson J.L., Turner S.P. Bone cancer: Diagnosis and Treatment Principles. Am Fam Physician 2018;98(4):205–13. PMID: 30215968.
4. American Cancer Society. Survival rates for Ewing tumors. [Electronic resource]: https://www.cancer.org/cancer/ewing-tumor/detection-diagnosis-staging/survival-rates.html (appeal date 09.05.2020).
5. Leavey P.J., Mascarenhas L., Marina N., Chen Z., Krailo M., Miser J., Brown K., Tarbell N., Bernstein M.L., Granowetter L., Gebhardt M., Grier H.E.; Children Oncology Group. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multimodality therapy: A report from the Childrenʼs Oncology Group. Pediatr Blood Cancer 2008;51(3):334–8. doi: 10.1002/pbc.21618.
6. Yu H., Ge Y., Guo L., Huang L. Potential approaches to the treatment of Ewingʼs sarcoma. Oncotarget 2017;8(3):5523–39. doi: 10.18632/oncotarget.12566.
7. Ritter J., Bielack S.S. Osteosarcoma. Ann Oncol 2010;21 Suppl 7:vii320–5. doi: 10.1093/annonc/mdq276.
8. St. Jude Children’s Research Hospital. Osteosarcoma [Electronic resource]: https://www.stjude.org/disease/osteosarcoma.html (appeal date 10.05.2020).
9. American Cancer Society. Survival rates for Ewing tumors. [Electronic resource]: https://www.cancer.org/cancer/osteosarcoma/detection-diagnosis-staging/survival-rates.html (appeal date 10.05.2020).
10. Shaikh A.B., Li F., Li M., He B., He X., Chen G., Guo B., Li D., Jiang F., Dang L., Zheng S., Liang C., Liu J., Lu C., Liu B., Lu J., Wang L., Lu A., Zhang G. Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma. Int J Mol Sci 2016;17(4):506. doi: 10.3390/ijms17040506.
11. Brenner J.C., Feng F.Y., Han S., Patel S., Goyal S.V., Bou-Maroun L.M., Liu M., Lonigro R., Prensner J.R., Tomlins S.A., Chinnaiyan A.M. PARP-1 inhibition as a targeted strategy to treat Ewingʼs sarcoma. Cancer Res 2012;72(7):1608–13. doi: 10.1158/0008-5472.CAN-11-3648.
12. Gourley C., Balmaña J., Ledermann J., Serra V., Dent R., Loibl S., Pujade-Lauraine E., Boulton S.J. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. J Clin Oncol 2019;37(25):2257–69. doi: 10.1200/JCO.18.02050.
13. Garnett M.J., Edelman E.J., Heidorn S.J., Greenman C.D., Dastur A., Lau K.W., Greninger P., Thompson I.R., Luo X., Soares J., Liu Q., Iorio F., Surdez D., Chen L., Milano R.J., Bignell G.R., Tam A.T., Davies H., Stevenson J.A., Barthorpe S., Lutz S.R., Kogera F., Lawrence K., McLaren-Douglas A., Mitropoulos X., Mironenko T., Thi H., Richardson L., Zhou W., Jewitt F., Zhang T., OʼBrien P., Boisvert J.L., Price S., Hur W., Yang W., Deng X., Butler A., Choi H.G., Chang J.W., Baselga J., Stamenkovic I., Engelman J.A., Sharma S.V., Delattre O., Saez-Rodriguez J., Gray N.S., Settleman J., Futreal P.A., Haber D.A., Stratton M.R., Ramaswamy S., McDermott U., Benes C.H. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483(7391):570–5. doi: 10.1038/nature11005.
14. Choy E., Butrynski J.E., Harmon D.C., Morgan J.A., George S., Wagner A.J., DʼAdamo D., Cote G.M., Flamand Y., Benes C.H., Haber D.A., Baselga J.M., Demetri G.D. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer 2014;14:813. doi: 10.1186/1471-2407-14-813.
15. Schafer E.S., Rau R.E., Berg S.L., Liu X., Minard C.G., Bishop A.J.R., Romero J.C., Hicks M.J., Nelson M.D. Jr., Voss S., Reid J.M., Fox E., Weigel B.J., Blaney S.M. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/ recurrent solid tumors including Ewing sarcoma: A Childrenʼs Oncology Group Phase 1 Consortium study (ADVL1411). Pediatr Blood Cancer 2020;67(2):e28073. doi: 10.1002/pbc.28073.
16. Heisey D.A.R., Lochmann T.L., Floros K.V., Coon C.M., Powell K.M., Jacob S., Calbert M.L., Ghotra M.S., Stein G.T., Maves Y.K., Smith S.C., Benes C.H., Leverson J.D., Souers A.J., Boikos S.A., Faber A.C. The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity. Clin Cancer Res 2019;25(5):1664–75. doi: 10.1158/1078-0432.CCR-18-0277.
17. LeRoith D., Roberts C.T. Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195(2):127–37. doi: 10.1016/s0304-3835(03)00159-9.
18. Scotlandi K., Benini S., Sarti M., Serra M., Lollini P.L., Maurici D., Picci P., Manara M.C., Baldini N. Insulin-like growth factor I receptor-mediated circuit in Ewingʼs sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996;56(20):4570–4. PMID: 8840962.
19. Van Maldegem A.M., Bovée J.V., Peterse E.F., Hogendoorn P.C., Gelderblom H. Ewing sarcoma: The clinical relevance of the insulinlike growth factor 1 and the poly-ADP-ribose-polymerase pathway. Eur J Cancer 2016;53:171–80. doi: 10.1016/j.ejca.2015.09.009.
20. Olmos D., Postel-Vinay S., Molife L.R., Okuno S.H., Schuetze S.M., Paccagnella M.L., Batzel G.N., Yin D., Pritchard-Jones K., Judson I., Worden F.P., Gualberto A., Scurr M., de Bono J.S., Haluska P. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010;11(2):129–35. doi: 10.1016/S1470-2045(09)70354-7.
21. Juergens H., Daw N.C., Geoerger B., Ferrari S., Villarroel M., Aerts I., Whelan J., Dirksen U., Hixon M.L., Yin D., Wang T., Green S., Paccagnella L., Gualberto A. Preliminary efficacy of the anti-insulinlike growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 2011;29(34):4534–40. doi: 10.1200/JCO.2010.33.0670.
22. Tap W.D., Demetri G., Barnette P., Desai J., Kavan P., Tozer R., Benedetto P.W., Friberg G., Deng H., McCaff ery I., Leitch I., Badola S., Chang S., Zhu M., Tolcher A. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol 2012;30(15):1849–56. doi: 10.1200/JCO.2011.37.2359.
23. Weigel B., Malempati S., Reid J.M., Voss S.D., Cho S.Y., Chen H.X., Krailo M., Villaluna D., Adamson P.C., Blaney S.M. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Childrenʼs Oncology Group. Pediatr Blood Cancer 2014;61(3):452–6. doi: 10.1002/pbc.24605.
24. Wagner L.M., Fouladi M., Ahmed A., Krailo M.D., Weigel B., DuBois S.G., Doyle L.A., Chen H., Blaney S.M. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Childrenʼs Oncology Group. Pediatr Blood Cancer 2015;62(3):440–4. doi: 10.1002/pbc.25334.
25. Fleuren E.D., Versleijen-Jonkers Y.M., Boerman O.C., van der Graaf W.T. Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives. Biochim Biophys Acta 2014;1845(2):266–76. doi: 10.1016/j.bbcan.2014.02.005.
26. Zwick E., Bange J., Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 2001;8(3):161–73. doi: 10.1677/erc.0.0080161.
27. Sulzbacher I., Birner P., Trieb K., Träxler M., Lang S., Chott A. Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol 2003;16:66–71. doi: 10.1097/01.MP.0000043522.76788.0A.
28. Bozzi F., Tamborini E., Negri T., Pastore E., Ferrari A., Luksch R., Casanova M., Pierotti M.A., Bellani F.F., Pilotti S. Evidence for activation of KIT, PDGFRα, and PDGFRβ receptors in the Ewing sarcoma family of tumors. Cancer 2007;109:1638–45. doi: 10.1002/cncr.22587.
29. Yu X.-W., Wu T.-Y., Yi X., Ren W.-P., Zhou Z.-B., Sun Y.-Q., Zhang C.-Q. Prognostic significance of VEGF expression in osteosarcoma: A meta-analysis. Tumour Biol 2014;35:155–60. doi: 10.1007/s13277-013-1019-1.
30. Bailey K., Cost C., Davis I., Glade-Bender J., Grohar P., Houghton P., Isakoff M., Stewart E., Laack N., Yustein J., Reed D., Janeway K., Gorlick R., Lessnick S., DuBois S., Hingorani P. Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Childrenʼs Oncology Group (COG) New Agents for Ewing Sarcoma Task Force. F1000Res 2019;8:F1000 Faculty Rev-493. doi: 10.12688/f1000research.18139.1.
31. Duff aud F., Mir O., Boudou-Rouquette P., Piperno-Neumann S., Penel N., Bompas E., Delcambre C., Kalbacher E., Italiano A., Collard O., Chevreau C., Saada E., Isambert N., Delaye J., Schiffler C., Bouvier C., Vidal V., Chabaud S., Blay J.Y.; French Sarcoma Group. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 2019;20(1):120–33. doi: 10.1016/S1470-2045(18)30742-3.
32. Davis L.E., Bolejack V., Ryan C.W., Ganjoo K.N., Loggers E.T., Chawla S., Agulnik M., Livingston M.B., Reed D., Keedy V., Rushing D., Okuno S., Reinke D.K., Riedel R.F., Attia S., Mascarenhas L., Maki R.G. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol 2019;37(16):1424–31. doi: 10.1200/JCO.18.02374.
33. Aggerholm-Pedersen N., Rossen P., Rose H., Safwat A. Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience. Transl Oncol 2020;13(2):295–9. doi: 10.1016/j.tranon.2019.12.001.
34. Italiano A., Mir O., Mathoulin-Pelissier S., Penel N., PipernoNeumann S., Bompas E., Chevreau C., Duff aud F., Entz-Werlé N., Saada E., Ray-Coquard I., Lervat C., Gaspar N., Marec-Berard P., Pacquement H., Wright J., Toulmonde M., Bessede A., Crombe A., Kind M., Bellera C., Blay J.Y. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2020;21(3):446–55. doi: 10.1016/S1470-2045(19)30825-3.
35. Nurmio M., Toppari J., Zaman F., Andersson A.M., Paranko J., Söder O., Jahnukainen K. Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat. Int J Androl 2007;30(4):366–76; discussion 376. doi: 10.1111/j.1365-2605.2007.00755.x.
36. McGary E.C., Onn A., Mills L., Heimberger A., Eton O., Thomas G.W., Shtivelband M., Bar-Eli M. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not aff ect tumorigenicity in vivo. J Invest Dermatol 2004;122(2):400–5. doi: 10.1046/j.0022-202X.2004.22231.x.
37. Bond M., Bernstein M.L., Pappo A., Schultz K.R., Krailo M., Blaney S.M., Adamson P.C. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children’s Oncology Group study. Pediatr. Blood Cancer 2008;50:254–8. doi: 10.1002/pbc.21132.
38. Grignani G., Palmerini E., Ferraresi V., D’Ambrosio L., Bertulli R., Asaftei S.D., Tamburini A., Pignochino Y., Sangiolo D., Marchesi E. Capozzi F., Biagini R., Gambarotti M., Fagioli F., Casali P.G., Picci P., Ferrari S., Aglietta M.; Italian Sarcoma Group. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: A non-randomised phase 2 clinical trial. Lancet Oncol 2015;16:98–107. doi: 10.1016/S1470-2045(14)71136-2.
39. Oldham S., Hafen E. Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control. Trends Cell Biol 2003;13(2):79–85. doi: 10.1016/s0962-8924(02)00042-9.
40. OʼReilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66(3):1500–8. doi: 10.1158/0008-5472.CAN-05-2925.
41. Kurmasheva R.T., Dudkin L., Billups C., Debelenko L.V., Morton C.L., Houghton P.J. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009;69(19):7662–71. doi: 10.1158/0008-5472.CAN-09-1693.
42. Naing A., LoRusso P., Fu S., Hong D.S., Anderson P., Benjamin R.S., Ludwig J., Chen H.X., Doyle L.A., Kurzrock R. Insulin growth factorreceptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewingʼs sarcoma family tumors. Clin Cancer Res 2012;18(9):2625–31. doi: 10.1158/1078-0432.CCR-12-0061.
43. Schwartz G.K., Tap W.D., Qin L.X., Livingston M.B., Undevia S.D., Chmielowski B., Agulnik M., Schuetze S.M., Reed D.R., Okuno S.H., Ludwig J.A., Keedy V., Rietschel P., Kraft A.S., Adkins D., Van Tine B.A., Brockstein B., Yim V., Bitas C., Abdullah A., Antonescu C.R., Condy M., Dickson M.A., Vasudeva S.D., Ho A.L., Doyle L.A., Chen H.X., Maki R.G. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol 2013;14(4):371–82. doi: 10.1016/S1470-2045(13)70049-4.
44. Okouneva T., Azarenko O., Wilson L., Littlefield B.A., Jordan M.A. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 2008;7(7):2003–11. doi: 10.1158/1535-7163.MCT-08-0095.
45. Kolb E.A., Gorlick R., Reynolds C.P., Kang M.H., Carol H., Lock R., Keir S.T., Maris J.M., Billups C.A., Desjardins C., Kurmasheva R.T., Houghton P.J., Smith M.A. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 2013;60(8):1325–32. doi: 10.1002/pbc.24517.
46. Schafer E.S., Rau R.E., Berg S., Liu X., Minard C.G., DʼAdamo D., Scott R., Reyderman L., Martinez G., Devarajan S., Reid J.M., Fox E., Weigel B.J., Blaney S.M. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Childrenʼs Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 2018;65(8):e27066. doi: 10.1002/pbc.27066.
47. Schettini F., De Santo I., Rea C.G., De Placido P., Formisano L., Giuliano M., Arpino G., De Laurentiis M., Puglisi F., De Placido S., Del Mastro L. CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. Front Oncol 2018;8:608. doi: 10.3389/fonc.2018.00608.
48. Kennedy A.L., Vallurupalli M., Chen L., Crompton B., Cowley G., Vazquez F., Weir B.A., Tsherniak A., Parasuraman S., Kim S., Alexe G., Stegmaier K. Functional, chemical genomic, and superenhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. Oncotarget 2015;6(30):30178–93. doi: 10.18632/oncotarget.4903.
49. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cellcycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366(6456):704–7. doi: 10.1038/366704a0.
Рецензия
Для цитирования:
Моргачева Д.А., Панова Д.Ю., Белогурова М.Б. Таргетная терапия в лечении метастатических, рецидивных и рефрактерных форм саркомы Юинга и остеогенной саркомы. Обзор литературы. Российский журнал детской гематологии и онкологии (РЖДГиО). 2021;8(1):57-63. https://doi.org/10.21682/2311-1267-2021-8-1-57-63
For citation:
Morgacheva D.A., Panova D.Yu., Belogurova M.B. Targeted therapy in metastatic, recurrent and refractory Ewing sarcoma and osteogenic sarcoma. Review of literature. Russian Journal of Pediatric Hematology and Oncology. 2021;8(1):57-63. (In Russ.) https://doi.org/10.21682/2311-1267-2021-8-1-57-63
Просмотров:
1297
Послать статью по эл. почте 